Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 1 to 10 of 281 total matches.
Table: Some Drug Interactions with Drugs for IBD (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
Table: Some Drug Interactions with Drugs for IBD (online only) ...
View the Table: Some Drug Interactions with Drugs for IBD
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e114 doi:10.58347/tml.2023.1680c | Show Introduction Hide Introduction
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors ...
Opioids delay gastric emptying and the absorption of many
oral drugs, including the P2Y12 inhibitors clopidogrel (Plavix,
and generics), prasugrel (Effient, and generics), and ticagrelor
(Brilinta), which are commonly used for initial treatment of
acute coronary syndrome (ACS). An article in our February 25,
2019 issue reviewed studies showing that coadministration
of opioids delayed and decreased absorption of oral P2Y12
inhibitors and increased platelet reactivity. Recently published
clinical outcomes data may add to these concerns.
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
............................................. p 196-197 Some Antidepressant Drug Interactions .................................online
When SSRIs ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
reactions in aspirin-sensitive patients.
Drug Interactions – NSAIDs can decrease the
effectiveness ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
as 12.5-25 mcg/day.
Administration and Drug Interactions – LT4 should be
taken with water on an empty ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
for
vascular disease, particularly diabetes.
Drug Interactions – Triptans should not be used
within 24 hours ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Lipid-Lowering Drugs
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
, but their cardiovascular and mortality
benefits far outweigh these risks.6,7
Drug Interactions – Statin-induced myopathy ...
Cholesterol management guidelines from the
American College of Cardiology/American Heart
Association Task Force were last published in 2019.
Drugs for Bipolar Disorder
The Medical Letter on Drugs and Therapeutics • Apr 01, 2024 (Issue 1699)
..........................................................p 52
Some Drug Interactions with Mood-Stabilizing Drugs ......p 53
Some Drug Interactions ...
Bipolar disorder is characterized by episodes of
mania, hypomania, and depression. Recurrences of
manic or (more frequently) depressive symptoms
are common. About 15-20% of patients with bipolar
disorder die by suicide.
Med Lett Drugs Ther. 2024 Apr 1;66(1699):49-54 doi:10.58347/tml.2024.1699a | Show Introduction Hide Introduction
Drugs for Hypertension
The Medical Letter on Drugs and Therapeutics • May 27, 2024 (Issue 1703)
adjustments may be needed for renal or hepatic impairment or for drug interactions.
2. Approximate WAC for 30 ...
American College of Cardiology/American Heart
Association (ACC/AHA) guidelines for treatment of
hypertension were last published in 2018. Treatment
of hypertensive urgencies and emergencies is not
discussed here.
Med Lett Drugs Ther. 2024 May 27;66(1703):81-8 doi:10.58347/tml.2024.1703a | Show Introduction Hide Introduction
Drugs for Chronic Insomnia
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
.
Drug Interactions – Eszopiclone, zolpidem, and (to a
lesser extent) zaleplon are metabolized by CYP3A4 ...
Cognitive behavioral therapy for insomnia (CBT-I) is
recommended for initial treatment of chronic insomnia.
CBT-I includes stimulus control, sleep education
and hygiene, sleep restriction, relaxation training, and
cognitive therapy. When CBT-I alone is not effective,
pharmacologic treatment should be added.
Med Lett Drugs Ther. 2023 Jan 9;65(1667):1-6 doi:10.58347/tml.2023.1667a | Show Introduction Hide Introduction